What is HC Wainwright’s Forecast for EYPT FY2024 Earnings?

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of EyePoint Pharmaceuticals in a report released on Monday, November 11th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($2.15) for the year, down from their prior estimate of ($2.09). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

A number of other analysts have also recently weighed in on the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Scotiabank started coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. Robert W. Baird dropped their price objective on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Finally, Chardan Capital raised their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

EyePoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $9.17 on Thursday. EyePoint Pharmaceuticals has a 1 year low of $5.86 and a 1 year high of $30.99. The stock has a market cap of $490.78 million, a P/E ratio of -4.59 and a beta of 1.50. The stock has a 50-day simple moving average of $9.74 and a 200-day simple moving average of $9.85.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in EYPT. Patient Square Capital LP acquired a new stake in shares of EyePoint Pharmaceuticals in the third quarter valued at about $10,882,000. RA Capital Management L.P. acquired a new position in shares of EyePoint Pharmaceuticals in the 1st quarter valued at about $19,401,000. Point72 Asset Management L.P. acquired a new position in EyePoint Pharmaceuticals in the second quarter valued at approximately $5,488,000. Cubist Systematic Strategies LLC boosted its position in EyePoint Pharmaceuticals by 842.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 476,250 shares of the company’s stock valued at $4,143,000 after purchasing an additional 425,717 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of EyePoint Pharmaceuticals by 17.8% during the first quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock worth $49,530,000 after acquiring an additional 362,168 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.